Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00850564 · ClinicalTrials.gov registry record · NA

Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men

A NA study of Healthy Volunteers, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
15
Enrollment target
1
Study location

NCT00850564: Completed NA study of Healthy Volunteers, sponsored by Massachusetts General Hospital.

NCT00850564 is a NA study of Healthy Volunteers that has completed, run by Massachusetts General Hospital. The registered enrollment target is 15 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00850564, a NA study of Healthy Volunteers, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

The purpose of this trial is to examine the short-term effects of Growth Hormone Releasing Hormone (GHRH, tesamorelin) administration in healthy men. We hypothesize that GHRH will increase GH pulse height and will not affect insulin sensitivity.

Primary Outcome

Outcome is mean overnight growth hormone at 2 weeks (i.e., following 2 weeks of treatment with growth hormone releasing hormone). Growth hormone was measured overnight (from 8pm-7:40am) by frequent blood sampling, and the mean is the average of these frequent measurements. The mean measurement at 2 weeks is given here, and, in the statistics section, is statistically compared with the mean measurement before treatment.

Conditions Studied

Interventions

  • DRUG Growth Hormone Releasing Hormone (Tesamorelin)

Study Locations (1)

Massachusetts

  • MGH - Boston

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2009-02
Est. Completion 2010-04
Phase NA
Massachusetts General Hospital

2,032 total trials

What the finished NCT00850564 record still lists

NCT00850564 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 1 intervention - of which Growth Hormone Releasing Hormone (Tesamorelin) is the first listed.

NCT00850564 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00850564 about?

NCT00850564 is a clinical study titled "Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men". The purpose of this trial is to examine the short-term effects of Growth Hormone Releasing Hormone (GHRH, tesamorelin) administration in healthy men. We hypothesize that GHRH will increase GH pulse height and will not affect insulin sensitivity.

What is the current status of trial NCT00850564?

This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2009-02. Estimated completion is 2010-04.

What conditions does trial NCT00850564 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT00850564?

The interventions under investigation include: Growth Hormone Releasing Hormone (Tesamorelin) (DRUG).

Who is sponsoring clinical trial NCT00850564?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00850564 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00850564's enrollment target sits among peer trials

15 243rd of 283 higher than 40 of 283 other Healthy Volunteers trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Volunteers trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00850564, the US trial registry maintained by the National Library of Medicine. NCT00850564 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.